Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

March 28, 2023

NASDAQ US Health Care Biotechnology earnings 38 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thank you very much, operator, and hello everyone on this afternoon's call. We're glad you could join us as Corvus Pharmaceuticals discusses its business update and financial results for the fourth quarter and the full 2022 year. With us to walk through those results and updates are our Chief Executive Officer, Richard Miller; our Chief Financial Officer, Leiv Lea; and James Rosenbaum, Senior Vice President of Research. Members of our executive team will begin with some prepared comments, and following that, we'll open things up for questions and answers. Please keep in mind that everything management says today, as well as any answers given to your questions, will include forward-looking statements. These forward-looking statements are based on what we estimate and assume right now, and they come with risks and uncertainties. Because of those, what actually happens could end up being quite different from what those statements suggest or imply. Those risks and uncertainties include the ones laid out in Corvus's annual report on Form 10-K, which went to the SEC today, along with the other documents the company periodically files there. Unless the law demands it, the company isn't taking on any duty to publicly update or revise any forward-looking statements. So with all that covered, I want to hand things over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. To kick things off, I'll give a brief rundown of our financial results for Q4 and the full year 2022, and after that I'll hand things over to Richard for an update on the business. R&D spending during the fourth quarter of 2022 came to $4.1 million, versus $4.8 million in the comparable quarter of 2021. That $0.7 million drop was mainly driven by lower personnel costs. For the entire 2022 year, R&D expenses reached $24.5 million, compared with $29.1 million across all of 2021. Our net loss in Q4 of 2022 was $9.8 million, which included a $4.6 million non-cash loss tied to Angel Pharmaceuticals, versus a net loss of $9.2 million in the same quarter of 2021, which included a $2.6 million non-cash loss tied to Angel. For the full year 2022, the net loss came to $41.3 million, including a $10 million non-cash loss tied to Angel, compared with a net loss of $43.2 million for the full year 2021, which included a $4.8 million non-cash loss tied to Angel. Total stock compensation expense for Q4 and the full year 2022 was $0.6 million and $2.7 million, respectively, versus $0.7 million and $4.2 million in the equivalent periods of 2021. As of December 31st, 2022, Corvus held cash equivalents and marketable securities amounting to $42.3 million, compared with $69.5 million as of December 31st, 2021. Turning to the future, we anticipate that net cash used in operating activities for the full year 2023 will land somewhere between $19 million and $22 million. Taken at the midpoint, that represents a 24% reduction from 2022, which shows how we continue to concentrate on carefully controlling our cash burn by prioritizing our strongest opportunities and setting up collaborations that assist in advancing our candidates. Given that trajectory and our emphasis on CPI-818, we're confident our cash will give us runway into 2024. At this point I'll pass the call to Richard, who will go into more detail about our strategy and plans.

Richard Miller

executive
#3

Thanks, Leiv, and hello, everyone, this afternoon. We appreciate you being on the call with us today for this update on our business. To begin, I'll point out three significant recent developments that, in our view, further highlight Corvus' chance to move CPI-818 forward in oncology and back our decision to make this program our priority. Number one, compelling data. Our clinical trial is enrolling at a faster pace, and results in peripheral T-cell lymphoma remain encouraging, with tumor responses that are deep and lasting. Beyond that, we've found a biomarker that ought to let us choose the patients most likely to gain from CPI-818, which matters a great deal as we prepare for our next trial. Two, and this leads into the second recent development, the route to a registrational trial. In a recent communication, the U.S. Food and Drug Administration signaled that it wants us to ask for a meeting to talk about a randomized phase III registration clinical trial for CPI-818. We expect that meeting to happen within the next few months. Three, moving into solid tumors. At AACR, we will share fresh preclinical data showing that 818 triggers antitumor immune responses against solid tumors, which widens what ITK inhibition could do in cancer. With that as a starting point, I'll now go over the momentum we've generated with 818 during the past several months and the main components of the development plan for T-cell lymphoma. CPI-818 is a highly specific covalent ITK inhibitor, and it attaches to ITK in a manner comparable to how ibrutinib attaches to BTK. In our view, the chance that CPI 818 offers by targeting T cells resembles what BTK inhibitors and anti-CD20 antibodies achieve by targeting B cells in treating B-cell lymphomas and autoimmune diseases; we're following a comparable playbook. Lymphoma data speeds up development, and after that we broaden into other cancers and immune diseases. Our grasp of what ITK does in the immune system has grown stronger thanks to the ongoing T-cell lymphoma clinical trial we're running as well as further laboratory and preclinical animal studies. Put simply, the more we learn, the more we think eight one eight holds wider possibilities across several areas, among them solid tumors, autoimmunity, and allergy. We've demonstrated that ITK is a key target within the immune system, with a significant role in T helper cell differentiation. More precisely, at the ASH meeting in December, we shared data indicating that CPI eight one eight alters the immune function of T cells by inhibiting both Th2 and Th17 cells and shifting the balance toward Th1 cells. That matters particularly for cancer therapy, since Th1 cells are needed to eliminate tumor cells, while Th2 and Th17 cells are the ones to blame for numerous autoimmune and allergic diseases. So far as we know, no other selective ITK inhibitors are in clinical development right now, and we consider our intellectual property position covering 818, ITK inhibitors, and methods of use to be strong. Given all of the above, we've made development of CPI-818 our priority and are pursuing a focused strategy in T-cell lymphomas to build value efficiently with the resources we already have. Looking more closely at the scientific and clinical progress behind CPI-818, we've ticked several key boxes that lower the risk on our lead indication and back up the wider promise of ITK inhibition across multiple diseases. We managed to work out the dosing as well as the biologic and immune effects of 818, both in vitro in preclinical models and in our phase I clinical trial. That matters especially when it comes to dosing, because bringing about Th1 skewing calls for a different dose than simply blocking T-cell receptor signaling broadly — an idea we were the first to pursue. Activity is showing up in our phase I T-cell lymphoma trial among patients whose refractory peripheral T-cell lymphoma, or PTCL, has resisted other treatment. Enrollment into the 200 mg cohort has carried on and picked up speed since the previous data update at ASH in December. By February 15, 2023, we had 20 patients enrolled, 13 of whom can be evaluated for tumor response. The refreshed data highlights are as follows. We have 1 complete response lasting 24 months, plus one equivocal complete response lasting 13+ months that is awaiting a PET scan to confirm CR. That case involved a patient who had previously achieved a partial response and keeps showing tumor regression. There is one nodal CR lasting 21 months and a partial response lasting seven months. 10 patients remain on therapy, seven of whom have not yet been evaluated for tumor response. The swimmer and waterfall tumor plots for these patients appear in our Q4 results press release issued today. We aim to share updated data from this cohort at a medical meeting later this year, most likely the International Conference on Malignant Lymphomas, taking place in June in Lugano, Switzerland. Adding further support to this opportunity, we think we've found an important predictive biomarker that ought to let us enrich our trials for the patients most likely to benefit from CPI-818. We now understand that 818 triggers a host anti-tumor cell-mediated response that depends on properly functioning T cells. What we've seen is that a response requires a minimum absolute lymphocyte count, or ALC, above 900 per cubic milliliter of blood. A normal ALC falls between 1,000 and 4,000. Some of the data is summarized in today's press release. In short, objective tumor responses occurred in four of eight patients whose ALC was above 900, and all eight showed disease control with a median progression-free survival of 28.1 months. Among five patients with ALC below 900, no responses appeared, and PFS in that group comes to only 2.1 months. This biomarker is simple to measure, aligns with 818's presumed mechanism of action, and judging by our experience so far, roughly 70% of patients satisfy this criterion. This biomarker has now been added as an eligibility criterion for our ongoing phase I trial. As I noted in my introduction, we recently heard from the FDA concerning our clinical development plans for CPI-818. Given how many patients are currently signing up for our phase I/Ib study that's still underway, we feel the total treated in it would yield sufficient safety and early efficacy findings to guide how a registration trial should be designed. Following FDA advice, our next step is to seek a meeting with the agency about a registration clinical trial. Under our present approach, we'd run a randomized study in refractory PTCL that pits CPI-818 against standard single agent chemotherapy, with our new ALC biomarker guiding which patients get selected. For standard single agent chemotherapy, median PFS is anticipated to be 3 months. We think 818 is capable of a meaningful PFS improvement over that, something a trial of only modest size — roughly 150 patients altogether — could show. Potentially, this study would yield definitive randomized evidence within a timeline comparable to the single arm phase II design we had planned before, which called for an interim analysis plus a related FDA meeting; such an approach aligns with industry guidance FDA released just yesterday. In that paper, the topic is what to consider for one randomized controlled trial capable of backing accelerated approval via a surrogate endpoint such as response rate while, through continued follow-up, verifying or confirming clinical benefit to support full approval using an endpoint like PFS.

Richard Miller

executive
#4

Here's another important piece of news about 818: a fresh opportunity involving solid tumors. At the AACR meeting, just a few weeks from now, we're going to share preclinical results across multiple models showing that 818 boosts antitumor immune responses against solid tumors, working through modulation of T cell differentiation and the resulting rise in T effector cells within tumors. We've already observed this in our ongoing T cell lymphoma study, and it will be presented at the Lugano meeting in June; this body of work underscores how important and valuable ITK is as a therapeutically actionable target. When it comes to immune diseases, we've shown 818 activity, including in preclinical models of psoriasis, asthma, lupus, and fibrosis. We also showed proof of concept for 818 in atopic dermatitis using companion dogs that develop the disease naturally, which closely mirrors human disease. Back in February, we expanded the list of potential opportunities when researchers from UCSF presented new data showing CPI-818's potential to lessen the need for chronic HIV therapy. That UCSF team will keep investigating how ITK inhibition might support antiproliferative and block-and-lock HIV cure strategies. This work provides further validation of ITK's critical role in immune modulation; in the near term, we'll be laser-focused on enrollment in our ongoing phase I T-cell lymphoma trial and on meeting with FDA to talk about a randomized phase III registration trial; as for atopic dermatitis, we've made the decision to pause that work. Doing so lets us sharpen our focus on T-cell lymphoma and cancer and conserve cash while we continue pushing our R&D forward to further strengthen the foundation for using 818 in immune diseases. We're still excited about what 818 could do in atopic dermatitis. In a space that's getting more crowded by the day, we offer a novel approach with many possible advantages. Beyond the anticipated T-cell lymphoma milestones I just mentioned, there are other potential catalysts from our two remaining programs: ciforadenant, our adenosine A2A receptor antagonist, and mupadolimab, our B cell activating antibody that targets CD73. Sifo is right now in a phase Ib/phase II clinical trial as a possible first-line therapy for metastatic renal cell cancer, in a triplet combination with ipilimumab and nivolumab. The Kidney Cancer Research Consortium is running this trial, led by MD Anderson, with other member institutions taking part, among them Vanderbilt, Beth Israel Deaconess Medical Center, Duke, University of Michigan, University of Pennsylvania, and UT Southwestern; the trial rests on our 2018 publication showing synergy between ciforadenant and anti CTLA-4 antibody in preclinical tumor models, along with data from our phase I studies demonstrating ciforadenant's antitumor activity. Up to 60 patients are planned for enrollment, with endpoints of safety, tolerability, and antitumor activity. The primary endpoint is the percent of patients achieving deep responses, defined as CRs and PRs with tumor volume reduction greater than 50%. That speaks to our goal of raising the plateau on PFS and improving survival by adding ciforadenant. Past information has demonstrated that deep responses line up with extended progression-free survival, and roughly 32% of patients who receive Ipi and Nivo show them. Within those groups, the complete response rate sits at just about 10%. Just to remind everyone, this trial is single arm and open label. We expect to gain a solid sense of efficacy at an early point in the study. Turning to mupadolimab, Angel Pharmaceuticals, which is our partner, has begun enrolling patients in a phase I/phase Ib clinical trial over in China, testing mupa by itself and in combination with pembrolizumab among patients who have relapsed refractory non-small cell lung cancer, as well as among those with head and neck squamous cell cancer. To wrap up, we feel Corvus holds a distinctive position thanks to prioritizing 818, the ITK inhibitor furthest along in development. Among the important near-term milestones for our program is ongoing enrollment in our phase I/phase Ib at the 200 mg dose, which includes employing our new biomarker. Fresh data from our 818 phase I T-cell lymphoma trial is going to be shared at the Lugano meeting in June. There will be a meeting with FDA regarding a randomized phase III registration trial. From the programs driven by our partners, we expect interim data out of the SIFO trial by the middle of the year. We are eager to share updates on these important initiatives over the next few quarters. At this point I'll hand the call to the operator so we can move into the question and answer session. Operator?

Aydin Huseynov

analyst
#5

Hi there, good afternoon — Richard, if you don't mind. Thanks a lot for the update, and congratulations on the biomarker; it's a pretty solid biomarker. It looks like all 8 patients who responded at stable disease had an absolute lymphocyte count above 900. How about the rest? My understanding is there were 11 patients total. For the other three patients, what was the ALC? Just wondering.

Richard Miller

executive
#6

ALC was present in four out of eight patients. Among patients for whom we have tumor evaluations — sorry — eight had ALCs above 900. Objective responses, PRs or CRs, occurred in four of those eight. Eight out of eight — that is, the remaining four — had stable disease. Disease control was seen in all eight. Four of the eight had objective tumor responses. Concerning the other five patients whose ALCs were below 900: objective responses numbered zero, and disease control — how many? two. Naturally, when you look at the PFS curves, the duration of time to progression differs remarkably. As I said, 28 months versus two months. Incidentally, those two months closely resemble what chemotherapy shows, in our view.

Aydin Huseynov

analyst
#7

All right, that makes sense.

Richard Miller

executive
#8

This biomarker is one we're quite enthusiastic about. Let me explain the reasons. First, it aligns with how the drug works. Without normal lymphocytes, there's no way to activate the immune system — that's point one. Second, it's simple to quantify. You get it for nothing as part of a CBC, so from a complete blood count with differential, you derive the absolute lymphocyte count, and that happens daily for every single patient. Reason three: ALC is, you know, something oncologists are pretty familiar with. There are other tumors we're aware of in which absolute lymphocyte count serves as a prognostic marker too.

Aydin Huseynov

analyst
#9

Ah, all right. That definitely clears things up. Right, I see.

Richard Miller

executive
#10

And then there's one last item, Aydin, that slipped my mind.

Aydin Huseynov

analyst
#11

Right.

Richard Miller

executive
#12

Every person newly enrolled in the study we're currently running — those 7 individuals — you can check the swimmer plot included in the press release, I believe. The 7 arrows shown at the bottom portion of that swimmer plot represent patients who all came in under our updated criterion. In other words, each of them has a lymphocyte count above 900 per cubic millimeter.

Aydin Huseynov

analyst
#13

I want you to really emphasize this point. What are the implications for possibly pairing the ITK inhibitor with chemo? Can that even be done, or not? What are the implications for shifting toward earlier lines of therapy? In earlier lines of treatment, you'd presumably anticipate patients having higher ALC, correct?

Richard Miller

executive
#14

That's completely accurate. It suggests that selecting patients sooner means more of them will qualify. There's no doubt about that. The fewer rounds of chemo someone has undergone, the less worn down they are, and the greater their lymphocyte count is going to be; that's certain, I'd say. Second, regarding chemo, patients who receive it do better tolerably when their absolute lymphocyte counts are on the higher side. As you're aware, T-cell lymphoma is inherently a highly immunosuppressive illness. These individuals suffer from numerous immune issues. Beyond that, when they're lymphopenic, when their normal lymphocytes are diminished, they are truly crippled immunologically; this aligns well with the mechanism of action we hypothesize, which, as I attempted to convey during my talk, we now think can reach past T-cell lymphoma into additional cancers.

Aydin Huseynov

analyst
#15

Right. Right, that's actually quite intriguing, provided it's...

Richard Miller

executive
#16

Right. I.

Aydin Huseynov

analyst
#17

This could apply to additional tumor types too.

Richard Miller

executive
#18

Right. During the conference in Lugano, our team members — both those based here and the partners we work with at Peking University — carried out biopsies along with single-cell RNA sequencing, and the results demonstrate that within the tumors, T effector cells are not merely more numerous; their cytolytic capability, meaning their capacity to destroy, is also elevated.

Aydin Huseynov

analyst
#19

Right, right, got it, I understand. About that phase III registration question, the possible registration study — yes, it was published not long ago. In PTCL before, other drugs got approved using single-arm studies. Do you figure it's now fixed that we need a randomized phase III design, or could the FDA still follow that earlier precedent?

Richard Miller

executive
#20

I believe a randomized study works more in our favor. I see that as a positive. Let me explain. To begin with, if you launch a single-arm study, there's no guarantee you'll obtain results strong enough to win accelerated approval, even under the older rules — that's point one. Point two, you'd still need to meet with them, and you'd need to commit to a phase III definitive study, or already have the data ready for it. All of those activities would need to be underway beforehand. You'd need the data from your open label study. Your definitive study would have to be started and by then fully enrolled. When you add it all up, that's actually more effort and it takes more time. What I think serves us better here is that we can now run a randomized study, competing against chemotherapy. We can make a dealer's choice and select three or four drugs; we've already been talking about that with our experts. With those drugs, the expected median PFS comes to roughly 3 months, possibly shorter. In our single agent 818 arm, we need to beat that. The plan, you know, might be to check early and examine response rate. If you clear a threshold for response rate, you receive accelerated approval. Your definitive study is already underway, and then you wait on PFS. In this instance, I believe — and we need to do a bit more work running these numbers — PFS is so short in the chemo arm that I doubt you'd gain much time by checking response rate for accelerated approval, when just a, probably a few months more, and you'd have the definitive PFS data. Are you following that?

Aydin Huseynov

analyst
#21

Understood. Yes, that's logical. There's no need to hold off for something like 28 months.

Richard Miller

executive
#22

Correct. Exactly. The gap between the point where you've got your response rate and the point where you've got your PFS — you know, sufficient PFS data — is going to be fairly brief.

Aydin Huseynov

analyst
#23

Understood. Yes, you simply need to surpass that. All right; that's very clear.

Richard Miller

executive
#24

Aydin, what matters most here is that this one is a definitive trial. There's no need afterward to run a confirmatory trial. Clearly, it came out positive.

Aydin Huseynov

analyst
#25

All right, that's logical. That's logical. What's your expected timing for kicking off this trial?

Richard Miller

executive
#26

Our expectation is that we can get this trial underway prior to the year's end.

Aydin Huseynov

analyst
#27

Okay, I see. Understood. Thank you for fielding my questions. Congrats on the biomarker. Thanks.

Mara Goldstein

analyst
#28

Oh, wonderful. Thanks a lot for posing that. Hey, I just wanted to circle back briefly to the biomarker. Given that ALC has a typical range, do you have some kind of intuition regarding — with these patients, I realize you touched on this somewhat with earlier versus later lines, but — what share of patients would probably in fact have, you know, to hit that 900 cutoff you've pinpointed?

Richard Miller

executive
#29

All right, Mara, based on what we've seen up to this point — and right now, a substantial portion of the patients we're treating are later-line — roughly 70% of them have a baseline above 900. My sense is that if we were to treat people at an earlier stage, that proportion would likely rise.

Mara Goldstein

analyst
#30

All right, that's great. And I did have one more question regarding the gathering with the FDA concerning, you know, kicking off a registration program that you said would happen later in the year. Is anything standing in the way of your asking for that meeting — anything you have to complete before it takes place right now? It definitely speeds things up and alters your clinical plan.

Richard Miller

executive
#31

Okay, we need to put together a package that sums up our safety and efficacy data, along with a few other items. That's a gating item.

Mara Goldstein

analyst
#32

All right.

Richard Miller

executive
#33

That ought to be within our reach. I mean, there's nothing complicated about it. The know-how and the people we have can handle it.

Mara Goldstein

analyst
#34

Would it be fair to say that the timing you're looking at for this meeting falls somewhere near the close of Q2 or the start of Q3 — that sort of window?

Richard Miller

executive
#35

Yeah. Yes.

Mara Goldstein

analyst
#36

Perfect.

Richard Miller

executive
#37

I think we could be meeting with them in the next few months.

Mara Goldstein

analyst
#38

All right. Thank you. I truly appreciate that.

Roger Song

analyst
#39

Wonderful. I appreciate the update, and I appreciate you fielding the question. Perhaps just offering a remark on this possible phase III design, which as I grasp it involves looking at the biomarker ALC above 900, noticing the gap — an enormous gap — separating those treated and therefore those above versus those below 900. I'm simply wondering. What level of confidence do you have in that cutoff, and what amount of data do you truly need, how much additional data do you genuinely need to confirm that the threshold you'll submit to the FDA — or that you're anticipating — look, you've got seven patients who remain ongoing, and every one of them was chosen based on the ALC, and what's the probability you'd have to adjust the threshold? Likewise on dose selection, given that 200 mg is what you'll advance, and what's the probability you'd need to run further dose ranging or optimization prior to launching a pivotal study? Thank you.

Richard Miller

executive
#40

All right. Concerning that 900 ALC threshold, the numbers appear in the press release, and I referenced them: eight of eight with disease control, four of eight with objective response against zero in the other arm, 28 month PFS against 2 month. There's an extremely large gap separating 900 and above from below 900. Now, might we go with 1,000, 900, 1,000? Sure. That sits, well, essentially inside experimental error for the assay. The normal value is 1,000. Anything beneath 1,000 counts as lymphopenia. Other contexts have employed 1,000. It serves as a prognostic. For instance, it was a highly significant prognostic marker among patients hospitalized with COVID. When someone fell under 1,000, their outcomes were quite poor. With head and neck cancer, it's a prognostic marker. Additional cancers exist too where it has served as a prognostic marker. Meaning, whether lymphopenia is present, 1,000. We've found 900 to be a genuinely strong threshold, and we preferred to allow ourselves somewhat extra margin. I'd say that threshold is sensible when we examine our data. It's sensible given the mechanism of action. Honestly, I don't, I don't see any grounds to believe we'd, we'd want to alter it. Turning now to the dose, we currently possess considerable dosing knowledge. My sense is we won't need to investigate alternative doses. For one thing, we recognize that the 200 mg dose... To begin with, as you're aware, we examined 100, 200, 400, 600 mg BID; we recognize that 200 mg delivers close to full receptor occupancy. We conducted quite rigorous studies on that. In terms of occupying your receptor — your ITK target — 600 isn't superior to 200 mg, first of all. Secondly, greater efficacy shows up at 200 mg. Not just among our lymphoma patients — we observe it in animal models and in immune disease models. Some individuals have given this the name Goldilocks effect, or there's a phenomenon in which T cell differentiation gets influenced. Our view is that this works optimally at approximately 200 mg and 400 mg BID. If you push the dose too far up, what you wind up with is broad immunosuppression, and that's likely not desirable. From our perspective, the 200 mg dose appears quite favorable, whether you look at efficacy, mechanism of action, and so forth. Last of all, on the safety side, the majority of companies head to FDA wanting to employ the largest dose they've tested. Our position is actually going to be, "No, we don't want to employ the largest dose we tested. What we really want is to employ a dose equal to one-third of what we studied." Roger, does that address your question?

Roger Song

analyst
#41

Of course. I truly appreciate that. This is extremely useful. Thanks, Rich.

Li Watsek

analyst
#42

Hello; Virginia Lee here. This is Lee Wang Watsek. We really appreciate you answering our questions. Only two brief ones from me. About that 200 mg group, you mentioned that enrollment has picked up speed. Do you have any idea what could be behind that? For instance, might it come from information you've released, or are there additional reasons...

Richard Miller

executive
#43

Oh, that's quite evident.

Li Watsek

analyst
#44

Oh, my mistake.

Richard Miller

executive
#45

That's a simple one. It got moved up on account of ASH.

Li Watsek

analyst
#46

Got it.

Richard Miller

executive
#47

ASH meeting in December.

Li Watsek

analyst
#48

Thanks.

Richard Miller

executive
#49

All right. What folks witnessed at ASH was: wow, this mechanism of action is genuinely novel; it works in patients who are refractory. ASH — I'd say that's truly the moment. Naturally, we implemented a few changes to the protocol at approximately that time, just ahead of it, regarding enrollment based on lymphocyte count, and so on, and interest in this trial has grown considerably now.

Li Watsek

analyst
#50

Understood, thanks. Now shifting to the biomarker. Past that 900 cutoff, are you seeing any correlative information tied to responses at 900 or higher, such as linear correlations?

Richard Miller

executive
#51

Oh.

Li Watsek

analyst
#52

With the new patients you've signed up under these selective criteria, have you possibly observed any confirmation yet, or does it remain too soon to know?

Richard Miller

executive
#53

When it comes to there being a straight line linear correlation, my view is that we lack sufficient data and sufficient responses at this point to make such a claim.

Li Watsek

analyst
#54

All right.

Richard Miller

executive
#55

It's obvious that those achieving the greatest results have had levels within the normal zone. What I mean is, I believe a lymphocyte count of 4,000 was reached by one of our CRs, and that sits squarely in the normal range. A suspicion is developing among us that a connection may exist in that regard. As for the individuals newly enrolled, selection is now happening according to an ALC exceeding 900. Just keep watching for updates on that front. I think we are observing some genuinely fascinating developments there.

Li Watsek

analyst
#56

Excellent. Many thanks.

Richard Miller

executive
#57

That appears quite favorable. There's just one more thing I wanted to ask about. Certain additional biomarkers have caught our attention. We simply lack sufficient information at this point. Among the biomarkers that interest us, which we've discussed in the past, is a transcription factor known as GATA3, spelled G-A-T-A-3. GATA3 is found within TH2 helper T cells. Tumors that are GATA3 positive are unfavorable. Peripheral T-cell lymphomas that are GATA3 positive represent the worst case, the absolute worst. Every one of our responders is GATA3 positive.

Li Watsek

analyst
#58

All right, I understand. I understand, I'll make a note of that, and I truly appreciate it.

Richard Miller

executive
#59

Hi there?

Richard Miller

executive
#60

Right. I believe we dropped Titan Partners on that one. Does anyone else have something to ask? Nothing's coming through. Okay, then I'd like to express my appreciation to all of you for joining us on this call today, and we're eager to bring you up to date on the next of our quarterly conference calls. Many thanks. All the best.

Operator

operator
#61

That brings this call to a close. We appreciate your joining us for today's presentation. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.